Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 7/20 | 0.85 |
| ▸ | MAPT | P10636 | 3/20 | 0.85 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.85 |
| ▸ | TP53 | P04637 | 2/20 | 0.85 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.85 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.85 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.85 |
| ▸ | MEN1 | O00255 | 2/20 | 0.85 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.85 |
| ▸ | MTOR | P42345 | 1/20 | 0.85 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.85 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.85 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.85 |
| ▸ | THPO | P40225 | 1/20 | 0.85 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.85 |
| ▸ | FTO | Q9C0B1 | 1/20 | 0.85 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.82 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.82 |
| ▸ | LMNA | P02545 | 2/20 | 0.82 |
| ▸ | BLM | P54132 | 2/20 | 0.82 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12083012 | 0.92 | KDM4E (1.00) | KDM4EMAPTCYP2D6TP53ALOX15 | |
| SCHEMBL150459 | 0.92 | KDM4E (1.00) | KDM4EMAPTCYP2D6TP53ALOX15 | |
| SCHEMBL22215232 | 0.92 | KDM4E (1.00) | KDM4EMAPTCYP2D6TP53ALOX15 | |
| SCHEMBL12849250 | 0.92 | KDM4E (1.00) | KDM4EMAPTCYP2D6TP53ALOX15 | |
| SCHEMBL30142606 | 0.92 | KDM4E (1.00) | KDM4EMAPTCYP2D6TP53ALOX15 | |
| SCHEMBL150460 | 0.92 | KDM4E (1.00) | KDM4EMAPTCYP2D6TP53ALOX15 | |
| SCHEMBL2453645 | 0.92 | KDM4E (1.00) | KDM4EMAPTCYP2D6TP53ALOX15 | |
| SCHEMBL4104614 | 0.90 | KDM4E (0.81) | KDM4EMAPTCYP2D6TP53ALOX15 | |
| SCHEMBL4092540 | 0.90 | KDM4E (0.81) | KDM4EMAPTCYP2D6TP53ALOX15 | |
| Fumaric Acid SCHEMBL29360188 | 0.90 | KDM4E (1.00) | KDM4EMAPTCYP2D6TP53ALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2011146819-A2 | METHODS AND COMPOSITIONS FOR TREATMENT NF-κB-MEDIATED AND α7 INTEGRIN-SUPPRESSED DISEASES | DMD THERAPIES, LLC (US) | 2011-11-24 | — | — | WO | disclosed |
| US-20110224128-A1 | METHODS AND COMPOSITIONS FOR TREATMENT OF MUSCULAR DYSTROPHY | WHALEN ANNE | 2011-09-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110224128-A1 | METHODS AND COMPOSITIONS FOR TREATMENT OF MUSCULAR DYSTROPHY | PYGM, TNNC1, MYOF | KDM4E 2360/4885MAPT 2484/4885CYP2D6 4689/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.